Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER)

• Published in: International journal of clinical oncology Vol. 24; no. 10; pp. 1214 - 1222
• Main Authors: Moriwaki, Toshikazu, Sakai, Yoshinori, Ishida, Hiroyasu, Yamamoto, Yoshiyuki, Endo, Shinji, Kuramochi, Hideaki, Sato, Mikio, Hatachi, Yukimasa, Bando, Yoshiaki, Maeba, Takashi, Ikezawa, Kazuto, Shimada, Mitsuo, Amagai, Kenji, Morimoto, Masamitsu, Kobayashi, Kazuma, Tsuji, Akihito, Nishina, Tomohiro, Hyodo, Ichinosuke
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01.10.2019; Springer Nature B.V
• Subjects: Adenocarcinoma; Bevacizumab; Cancer Research; Chemotherapy; Colorectal cancer; Colorectal carcinoma; Disease control; Geriatrics; Immunotherapy; Irinotecan; Medicine; Medicine & Public Health; Metastases; Metastasis; Monoclonal antibodies; Nausea; Oncology; Original Article; Oxaliplatin; Proteinuria; Surgical Oncology; Survival; Targeted cancer therapy; Elderly; S-1; Colorectal cancer; Bevacizumab; Fluoropyrimidine
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-019-01465-3

Background Alternate-day administration of S-1 is thought to reduce toxicities. This phase II study evaluated S-1 on alternate days combined with bevacizumab as first-line treatment for elderly patients with metastatic colorectal cancer. Patients and methods Eligible patients had histologically proven colorectal adenocarcinoma, measurable metastatic lesions, age ≥ 75 years, Eastern Cooperative Oncology Group performance status ≤ 1, no previous chemotherapy, and refused oxaliplatin- or irinotecan-containing regimens. Patients received 40 mg, 50 mg, or 60 mg (body surface area ≤ 1.25 m 2 , > 1.25 to ≤ 1.50 m 2 , or > 1.50 m 2 , respectively) of S-1 twice orally on Sunday, Monday, Wednesday, and Friday every week. Bevacizumab (7.5 mg/kg) was administered every 3 weeks. The primary endpoint was progression-free survival. Results Of 54 enrolled patients, 50 patients were evaluated for efficacy and 53 for safety. The median age was 79 years (range 75–88 years). The median progression-free survival was 8.1 months (95% confidence interval (CI) 6.7–9.5 months). The median overall survival was 23.1 months (95% CI 17.4–28.8 months). The response rate was 44% (95% CI 30.2–57.8%), and the disease control rate was 88% (95% CI 79.0–97.0%). Grade 3 or higher hematologic, non-hematologic, and bevacizumab-related adverse events occurred in 9%, 11%, and 25% of patients, respectively. The most common grade 3 and 4 treatment-related adverse events were hypertension (11%), nausea (6%), fatigue (6%), anemia (6%), and proteinuria (6%). Only 6 patients discontinued treatment due to adverse events. Conclusion S-1 on alternate days combined with bevacizumab showed better tolerability and comparable survival compared with the results of similar studies.